Current Neuro-Oncology

Volume 28 Number 26
31 October 2026

Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 26, 31 October

Khouri C, Bibollet A, Bouchoucha Y, Combarel D, Delahousse J, Aerts I, Bourdeaut F, Tauziede-Espariat A, Metais A, Varlet P, Beccaria K, Blauwblomme T, Guida L, Benichi S, Kariyawasam D, Dangouloff-Ros V, Boddaert N, Sellami N, Dufour C, Simbozel M, Guerrini-Rousseau L, Geoerger B, Grill J, Leblond P, Abbou S.
Real-life efficacy and tolerance of trametinib in BRAF-rearranged low-grade gliomas: A multicenter study.
Eur J Cancer. 2026 Oct 2;248:117450. doi: 10.1016/j.ejca.2026.117450. PMID: 42858621˰ ˍ

Merino-Galan L, Arora S, Glatzer G, Jensen M, Rajendran A, Holland EC, Pattwell SS.
Transcriptomic analysis reveals differential regulation of synaptic components in pediatric and adult brain tumors.
bioRxiv [Preprint]. 2026 Oct 2:2026.09.30.755821. doi: 10.64898/2026.09.30.755821. PMID: 42856585. ˍ

Chaudhry K, Muniraj N, Lang H, Geiger A, Paul G, Dowlati E, Sohai D, Terao J, Yadavilli S, Sanchez C, Yvon E, Lazaraski C, Hwang E, Holdhoff M, Savoldo B, Cruz CR, Bollard C.
Functional Exhaustion Limits CAR-NK Therapy in Glioblastoma but Can Be Mitigated by Early Repeated Dosing.
Res Sq [Preprint]. 2026 Oct 4:rs.3.rs-10808000. doi: 10.21203/rs.3.rs-10808000/v1. PMID: 42856446. ˍ

Lee D, Chung SW, Kong B, Xie Y, Kang B, Yang J, Huang B, Rao D, Choi JS, Ra EA, Anastasiadis P, Lee G, Kim DH, Lim M, Suk JS.
Blood-brain barrier-traversing multivalent TGFβ trap for anti-cancer immunomodulation of gliomas.
bioRxiv [Preprint]. 2026 Oct 6:2026.10.05.756837. doi: 10.64898/2026.10.05.756837. PMID: 42926591. notes. ˍ

Sergeenko OM, Gabay S, Roth J, Ringel A, Dvir R, Constantini S.
Chemotherapy for Spinal Cord Intramedullary Pediatric Low-Grade Glioma-A Systematic Literature Review.
Pediatr Blood Cancer. 2026 Oct 5:e70734. doi: 10.1002/1545-5017.70734. PMID: 42831660. ˍ

Sah RK, Yan X, Louis L, Gonzales N, Tsogt U, He B, Hoefner LG, Lecomte L, Bartels M, Le Roux CA, Starner AC, Basili I, Ayrault O, Van Nostrand EL, Saulnier O, Zagozewski J, Werbowetski-Ogilvie TE.
RBFOX2 restrains oncogenic cell plasticity in Group 3 medulloblastoma.
bioRxiv [Preprint]. 2026 Oct 6:2026.10.02.756284. doi: 10.64898/2026.10.02.756284. PMID: 42926567. ˍ

Singnurkar A, Sahgal A, Lechtman E, Lim-Fat MJ, Graham SJ, Lipsman N, Maralani P, Pond G, Detsky JS.
Volumetric discordance between ¹⁸F-FET-PET/MRI and MRI-based radiotherapy target volumes in high-grade glioma: a prospective pilot study (FETSMaRT).
J Neurooncol. 2026 Oct 14;180(1):20. doi: 10.1007/s11060-026-05831-w. PMID: 42875659. Trial registration ID: NCT06499831˰ ˍ

Cox E, Tahbaz M, Matarese E, Wilson RL, Gonzalez Castro LN, Uno H, Cooney T, Lane J, Norris MK, Bona K, Aziz-Bose R, Dieli-Conwright CM.
Feasibility of High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumor and Young Adults With Isocitrate Dehydrogenase-Mutant Gliomas (HYPE): Protocol for a Randomized Controlled Trial.
JMIR Res Protoc. 2026 Oct 15;15:e88718. doi: 10.2196/88718. PMID: 42879323. Trial registration ID: NCT05740839. ˍ

Hickey J, Pack E, Arteaga D, Hodge J, Bhatia S, Han P, Feizi P, Miller L, Aulakh S.
Utility of Vorasidenib in IDH1 R132C-Mutant WHO Grade 2 Astrocytoma: A Case Report.
Onco Targets Ther. 2026 Oct 16;19:638827. doi: 10.2147/OTT.S638827. PMID: 42904143. ˍ

Schreck KC, Lal B, Zhou J, Lopez-Bertoni H, Holdhoff M, Ewesuedo R, Bhatia K, Chamberlain M, Laterra J.
Phase Ia Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS Exposure.
Cancer Res Commun. 2026 Oct 27;6(10):2519-2528. doi: 10.1158/2767-9764.CRC-26-0518. PMID: 42849034. Trial registration ID: NCT05933265. ˍ

Umana GE, Ciuffreda G, Cortese E, Corso C, Raffa G, Vecchio CR, Ranganathan S, Pettinato A, Curduman M, Spadola S, Ferini G, Viganò R, Brambilla F, DI Silvestre D, Torrente Y, Mauri P.
Familial Glioma in a Father and Son: Integrated Genomic and Multi-compartment Proteomic Profiling.
Anticancer Res. 2026 Oct 27;46(11):5997-6015. doi: 10.21873/anticanres.18433. PMID: 42946437. ˍ

Veronese S, Solari A, De Panfilis L, Bertocchi E, Lissoni B, Merli R, Salmaggi A, Silvani A, Rudà R, Fariselli L, Camporeale G, Fausti P, Gianola S, Castellini G, Sgromo S, Iacorossi L, Pace A.
Italian guideline on palliative care in adult patients with grade 3/4 gliomas.
Neurol Sci. 2026 Oct 30;47(11):900. doi: 10.1007/s10072-026-09523-1. PMID: 42957920˰ ˍ

Vrancianu CO, Necula M, Milea E, Siminea N, Cristian RE, Stoica A, Chifiriuc MC, Oancea B, Păun A, Petre I, Păun M.
Raman spectroscopy for glioma diagnosis toward precision neuro-oncology: A systematic review.
Crit Rev Oncol Hematol. 2026 Oct 31;228:105675. doi: 10.1016/j.critrevonc.2026.105675. PMID: 42966518. ˍ

Fontão P, Viana-Pereira M, Pinto-Ribeiro F, Junqueira T, Reis RM.
Outcomes of immunotherapy in medulloblastoma: a systematic review.
Oncologist. 2026 May 8;31(6):oyag109. doi: 10.1093/oncolo/oyag109. PMID: 41950392. ˍ

Guo D, Xie K, Lin J, Chen J, Zhang J, Lin M, Qu X, Hu W, Wang J, Liang D.
Gliomas grading prediction using multicenter 3T Magnetic Resonance Spectroscopy.
BMC Med Imaging. 2026 Jul 31;26(1):559. doi: 10.1186/s12880-026-02640-5. PMID: 42947054. ˍ

Chatterjee S, Kumar P, Kumar AS, Lei PJ, Datta M, Zhao Y, Ho WW, Talele NP, Andersson P, Duquette M, Kitahara S, Blanc L, Wong SJ, Kwanten WJ, Ebb DH, Yock TI, Dartois V, Fukumura D, Duda DG, Xu L, Kim HJ, Jain RK.
Targeting Tumor-derived Sphingosine Kinase 2 Unleashes Antitumor Immunity and Improves Survival of Mice with Group 3 Medulloblastoma.
bioRxiv [Preprint]. 2026 Aug 13:2026.08.12.744521. doi: 10.64898/2026.08.12.744521. PMID: 42845663. ˍ

Hou J, McMahon M, Ni AW, Wang Z, Taylor B, Loe T, Xie Y, Chang L, Gardeck A, Gokaslan Z, Dunsiger SI, Ren B, Chen CC, Odde DJ.
Ex vivo glioblastoma migration phenotypes define clinical recurrence and tumor heterogeneity.
bioRxiv [Preprint]. 2026 Sep 2:2026.08.31.748107. doi: 10.64898/2026.08.31.748107. PMID: 42922526. ˍ

Sun L, Markus LF, Sanchez JC, Lai TJ, Lee EQ, Li G, Kim J, Zhuang Z, Acevedo B, Everson RG, Mellinghoff IK, Aquilanti E, Nicolas Gonzalez Castro L, Ricardo McFaline-Figueroa J, Nayak L, Beroukhim R, Chong RA, Stone J, Kaley T, Schaff L, Wilcox J, Westergaard C, Russ A, Lavallee M, Chukwueke U, Van den Abbeele AD, Lim M, Ellingson BM, Reardon DA, Cloughesy TF, Prins RM, Wen PY.
Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial.
Nat Commun. 2026 Sep 5;17(1):10560. doi: 10.1038/s41467-026-77433-z. PMID: 42838943. Trial registration ID: NCT04606316. ˍ

Azizi L, He L, Bhaduri A, Liau LM, Kornblum HI, Pajonk F.
Exosome-Mediated Bidirectional Signaling Regulates Glioma Stem-Cell Homeostasis and Radiation-Induced Plasticity.
bioRxiv [Preprint]. 2026 Sep 8:2026.09.02.748690. doi: 10.64898/2026.09.02.748690. PMID: 42818566. ˍ

Lee WC, Salinas JJ, Gautam A, Cadet D, Banu MA, Nathanson DA, Dixon SJ.
High-throughput spheroid profiling reveals BMP-driven rewiring of glioma cell death responses.
bioRxiv [Preprint]. 2026 Sep 13:2026.09.10.750657. doi: 10.64898/2026.09.10.750657. PMID: 42818713. ˍ

Fu AZ, Mowforth OD, Chintapalli R, Brown S, Hardyman F, Mair R.
Receptor tyrosine kinase targeted therapies in glioblastoma: a systematic review.
Front Med (Lausanne). 2026 Sep 17;13:1928491. doi: 10.3389/fmed.2026.1928491. PMID: 42824982. ˍ

Amezquita-Contreras C, Bueno A, Arellano D, Ruvalcaba-Guerrero H, Johnson WE, Dono A, Esquenazi Y, Ballester LY.
Circulating tumor DNA as a liquid biopsy for glioma detection in cerebrospinal fluid and plasma: A systematic review and meta-analysis.
Neurooncol Adv. 2026 Sep 22;8(1):vdag253. doi: 10.1093/noajnl/vdag253. PMID: 42871623. ˍ

Furey CG, Chang R, Tien AC, Tovmasyan A, Mehta S, Sanai N.
Tissue-Based Trials: Windows of Opportunity in Neuro-Oncology Drug Development.
Hematol Oncol Clin North Am. 2026 Sep 28;40(6):955-966. doi: 10.1016/j.hoc.2026.08.007. PMID: 42805863. ˍ